<DOC>
	<DOCNO>NCT01691677</DOCNO>
	<brief_summary>Intranasal corticosteroids beneficial treatment acute rhinosinusitis . As adjunctive therapy oral antibiotic treatment , mometasone furoate dose 200 μg 400 μg twice daily , well tolerate significantly effective reduce symptom rhinosinusitis antibiotic therapy alone . Furthermore , addition fluticasone propionate xylometazoline antimicrobial therapy cefuroxime improve clinical success rate accelerate recovery patient history chronic rhinitis recurrent sinusitis present treatment acute rhinosinusitis . The present study plan assess effect nebulised beclomethasone dipropionate give add-on therapy standard care ( oral antibiotic ) treatment acute symptomatic rhinosinusitis . Antibiotic therapy physician ' discretion .</brief_summary>
	<brief_title>beCLomethasone Efficacy Acute Rhinosinusitis - CLEAR Study</brief_title>
	<detailed_description />
	<mesh_term>Sinusitis</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<criteria>1 . Subject 's write informed consent obtain prior studyrelated procedure 2 . Male female outpatient age 18 65 year ( inclusive ) . 3 . History previously diagnose recurrent chronic sinusitis necessitate antibiotic therapy judge investigator . 4 . Clinical diagnosis acute rhinosinusitis define , accord European Position Paper Rhinosinusitis Nasal Polyps 2007 ( 20 ) , sudden onset two relevant symptom &lt; 12 week , least one : Nasal blockage/obstruction/congestion , OR Nasal discharge ( anterior/posterior nasal drip ) ; AND second one : • Facial pain/pressure or/and reduction/loss sense smell . 5 . A cooperative attitude ability train use correctly nebuliser intranasal nose piece . 1 . Previous sinus surgery ; 2 . Sinus lavage within past 7 day ; 3 . Nasal polyposis important nasal septum deviation ; 4 . Antibiotic use ( route ) past 30 day ; 5 . Recurrent moderate epistaxis ; 6 . Chronic bacterial sinusitis evidence failure antimicrobial therapy ; 7 . Intranasal systemic use corticosteroid within past 30 day ; 8 . Chronic use corticosteroid immunosuppressive agent ; 9 . Immunocompromised state ; 10 . Diagnosis bronchial asthma chronic obstructive pulmonary disease ( COPD ) ; 11 . History clinically significant cardiac ( i.e . congestive heart failure severe hypertension ) , renal ( i.e . kidney failure ) , psychiatric ( i.e . depression mood disorder ) , hepatic ( i.e . cholestatic jaundice hepatic dysfunction ) , endocrine ( i.e . hyperthyroidism adrenal suppression ) pulmonary disease , laboratory test abnormality , whose sequelae and/or treatment interfere result treatment present study ; 12 . History psychiatric disease likely require treatment antidepressant drug study period treatment antidepressant drug past 2 week ; 13 . Diagnosis glaucoma prostatic hypertrophy ; 14 . History alcohol drug abuse ; 15 . Allergy , sensitivity intolerance study drug and/or study drug formulation ingredient ( e.g . corticosteroid ) ; 16 . Pregnant lactate woman woman physiologically capable become pregnant UNLESS meet follow definition postmenopausal : 12 month natural ( spontaneous ) amenorrhea 6 month spontaneous amenorrhea serum FSH level &gt; 40 mIU/mL use one follow acceptable method contraception . surgical sterilization ( e.g . bilateral tubal ligation , hysterectomy ) hormonal contraception ( implantable , patch , oral ) doublebarrier method ( double combination : IUD , male female condom spermicidal gel , diaphragm , sponge , cervical cap ) . A pregnancy test ( urine ) perform screen woman childbearing potential . 17 . Patients unlikely comply protocol unable understand nature , scope possible consequence study . 18 . Participation another trial past 12 week patient previously enrol study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>